The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
How Large Will The Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Be By 2030 Compared To Its 2026 Market Size?
The chronic obstructive pulmonary disease (copd) treatment market size has experienced robust expansion over recent years. It is projected to increase from $21.73 billion in 2025 to $22.9 billion by 2026, demonstrating a compound annual growth rate (CAGR) of 5.4%. This historical growth was primarily driven by factors including high smoking prevalence, the increasing aging population, higher air pollution levels, growing occupational dust exposure, and improved awareness of COPD.
The chronic obstructive pulmonary disease (copd) treatment market size is anticipated to undergo substantial growth in the upcoming years. It is projected to expand to $29.13 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 6.2%. This expansion during the forecast period can be attributed to factors such as the increasing adoption of combination therapies, the broadening of homecare treatment models, rising healthcare expenditure, an escalation in copd diagnosis rates, and innovation in inhalation drug delivery. Key developments expected during this timeframe include a growing uptake of triple combination inhaler therapies, an increasing shift towards home-based copd management, an intensified focus on early diagnosis and disease screening, the proliferation of generic and cost-effective copd medications, and greater use of non-pharmacological pulmonary rehabilitation.
Access Your Free Sample Report For In-Depth Market Analysis:
https://www.thebusinessresearchcompany.com/sample.aspx?id=10054&type=smp
Which Factors Are Influencing The Growth Of The Chronic Obstructive Pulmonary Disease (COPD) Treatment Market?
The rising occurrence of smoking is projected to drive the expansion of the chronic obstructive pulmonary disease (COPD) treatment market in the future. Smoking is defined as the act of drawing smoke, usually from ignited materials like tobacco, into the mouth. For individuals who smoke, COPD treatment is favored because it leads to better breathing, a higher quality of life, fewer severe flare-ups, greater exercise endurance, a longer lifespan, and better mental well-being. An illustrative example comes from July 2023, when the World Health Organization, an intergovernmental body situated in Switzerland, reported that tobacco claims the lives of over 8 million individuals annually, a figure that encompasses 1.3 million non-smokers exposed to second-hand smoke. Consequently, the rising frequency of smoking is fueling the expansion of the chronic obstructive pulmonary disease (COPD) treatment market.
Which Segment Categories Are Included In The Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Segment Analysis?
The chronic obstructive pulmonary disease (copd) treatment market covered in this report is segmented –
1) By Drug Class: Combination Therapy, Bronchodilators, Corticosteroids, Phosphodiesterase Type 4 Inhibitor, Mucokinetics, Other Drug Classes
2) By Type: Chronic Bronchitis, Emphysema
3) By End-User: Hospitals, Clinics, Homecare Settings
Subsegments:
1) By Combination Therapy: Long-Acting Beta-Agonists (LABA) + Inhaled Corticosteroids (ICS), Long-Acting Muscarinic Antagonists (LAMA) + LABA, Triple Therapy (LAMA + LABA + ICS)
2) By Bronchodilators: Short-Acting Beta-Agonists (SABA), Long-Acting Beta-Agonists (LABA), Long-Acting Muscarinic Antagonists (LAMA)
3) By Corticosteroids: Inhaled Corticosteroids (ICS), Oral Corticosteroids, Injectable Corticosteroids
4) By Phosphodiesterase Type 4 Inhibitor: Roflumilast, Other PDE4 Inhibitors
5) By Mucokinetics: Expectorants, Mucolytics
6) By Other Drug Classes: Antibiotics, Antivirals, Antifungal Agents
What Trends Are Influencing The Evolution Of The Chronic Obstructive Pulmonary Disease (COPD) Treatment Market?
Major companies in the chronic obstructive pulmonary disease (COPD) treatment market are focusing on innovative products such as Vilfuro-G to drive their market revenues. Vilfuro-G is the world’s first fixed-dose triple combination medication (FDC) engineered to effectively treat chronic obstructive pulmonary disease (COPD). For example, in November 2023, Lupin Limited, an India-based pharmaceutical company, launched Vilfuro-G. The product is offered in a fixed dose of one strength, and a once daily dosage is recommended. The introduction of Vilfuro-G is anticipated to significantly improve the lives of COPD patients and broaden Lupin’s respiratory product line, demonstrating the company’s dedication to providing patients and medical professionals with cutting-edge treatment options. Vilfuro-G is the sole fixed-dose combination (FDC) specifically designed to combine glycopyrronium bromide, vilanterol, and fluticasone furoate for the long-term treatment and management of moderate to severe COPD.
Who Are The Active Companies Shaping The Chronic Obstructive Pulmonary Disease (COPD) Treatment Market?
Major companies operating in the chronic obstructive pulmonary disease (copd) treatment market are Almirall S.A., AstraZeneca plc, Boehringer Ingelheim International GmbH, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Novartis AG, Teva Pharmaceutical Industries Ltd., Chiesi Farmaceutici S.p.A, Sunovion Pharmaceuticals Inc., Dr. Reddy’s Laboratories Ltd., Sanofi S.A, Theravance Biopharma Inc., Verona Pharmaceuticals plc, Pfizer Inc., Mylan N.V., Orion Corporation, Cipla Limited, Glenmark Pharmaceuticals Limited, Biocon Limited, Lupin Limited, Mundipharma International Limited
Get The Full Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Report:
Which Region Holds The Highest Market Share In The Chronic Obstructive Pulmonary Disease (COPD) Treatment Market?
North America was the largest region in the chronic obstructive pulmonary disease (COPD) treatment market in 2025. Asia-Pacific is expected to be the global chronic obstructive pulmonary disease (COPD) treatment market report during the fastest-growing region in the forecast period. The regions covered in the chronic obstructive pulmonary disease (copd) treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Report For Competitive Insights:
Browse Through More Reports Similar to the Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market 2026, By The Business Research Company
Chronic Obstructive Pulmonary Disease Copd Treatment Market Report 2026
Chronic Obstructive Pulmonary Disease Copd And Asthma Devices Market Report 2026
Anti Asthmatics And Copd Drugs Market 2026
https://www.thebusinessresearchcompany.com/report/anti-asthmatics-and-copd-drugs-market
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model